Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Kintara Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.05.
Current Consensus is
Hold
The current consensus among 2 contributing investment analysts is to hold stock in Kintara Therapeutics. This rating has held steady since September 2022, when it changed from a Buy consensus rating.
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Read More